US 12,303,521 B2
Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-PD1 or anti-PDL1 monoclonal antibody
Mark Albertella, Huddinge (SE)
Assigned to MEDIVIR AB, Stockholm (SE)
Appl. No. 17/431,686
Filed by MEDIVIR AB, Huddinge (SE)
PCT Filed Feb. 17, 2020, PCT No. PCT/SE2020/050175
§ 371(c)(1), (2) Date Aug. 17, 2021,
PCT Pub. No. WO2020/171757, PCT Pub. Date Aug. 27, 2020.
Claims priority of application No. 1950202-0 (SE), filed on Feb. 18, 2019.
Prior Publication US 2022/0117983 A1, Apr. 21, 2022
Int. Cl. A61K 31/675 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC A61K 31/675 (2013.01) [A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01)] 18 Claims
 
1. A method of treatment of a liver cancer in a mammal in need thereof, comprising the administration of a therapeutically effective amount of a compound of the formula I:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, with the concurrent or sequential treatment of the mammal with a therapeutically effective amount of a monoclonal antibody which blocks the binding of PD-L1 and/or PD-L2 to PD-1.